Kelderman, Sander <br/><br/>
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.  [electronic resource] 

 -  Cancer immunology, immunotherapy : CII  May 2014 
 - 449-58 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>1432-0851 
<br/><br/><label>Standard No.: </label>10.1007/s00262-014-1528-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal--therapeutic use<br/>Biomarkers, Tumor--analysis<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Ipilimumab<br/>Kaplan-Meier Estimate<br/>L-Lactate Dehydrogenase--blood<br/>Male<br/>Melanoma--drug therapy<br/>Middle Aged<br/>Skin Neoplasms--drug therapy<br/>Treatment Outcome<br/>Young Adult